NCT01563328View on ClinicalTrials.gov

A Study to Evaluate the Effect of Boceprevir and Telaprevir on Dolutegravir Pharmacokinetics in Healthy Adult Subjects (ING115697).

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 1, 2012

Primary Completion Date

May 1, 2012

Study Completion Date

May 1, 2012

Conditions
Infection, Human Immunodeficiency Virus
Interventions
DRUG

DTG

50 mg q24h

DRUG

BCV

800 mg q8h

DRUG

TVR

750 mg q8h

Trial Locations (1)

78744

GSK Investigational Site, Austin

Sponsors

Lead Sponsor

ViiV Healthcare

Collaborators (2)

Shionogi
GlaxoSmithKline
All Listed Sponsors
collaborator

Shionogi

INDUSTRY

collaborator

GlaxoSmithKline

INDUSTRY

lead

ViiV Healthcare

INDUSTRY